Recently, Hefei Lifang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Lifang Pharmaceutical") has received the "Acceptance Notification" issued by the National Medical Products Administration (NMPA) for the Marketing Authorization Application (MAA) of Relugolix Active Pharmaceutical Ingredient (API). Relevant details are hereby announced as follows:
I. Main Contents of the "Acceptance Notification"
Application Item: Marketing Authorization
Product Name: Relugolix
Acceptance Explanation: In accordance with the provisions of Article 32 of the Administrative Licensing Law of the People's Republic of China, after review, it is decided to accept the application.
Registration Number: Y20240001454 (Acceptance Number: CXHS2560***)
II. Relevant Information about Relugolix
Relugolix is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist. It can inhibit the synthesis and release of gonadotropins such as luteinizing hormone (LH) and follicle-stimulating hormone (FSH), reduce the levels of sex hormones including testosterone and estradiol, and is used for the treatment of hormone-dependent diseases including endometriosis, uterine fibroids, and prostate cancer. This application is for the chemical API used in the generic production of a drug not yet marketed in China. As of the date of this announcement, no relevant pharmaceutical preparations have been approved for marketing in China. In addition to the Company, 10 enterprises have completed registration and filing for this API, with all registration statuses marked as "I" (API/excipient/package material not yet passed the joint review and approval with preparations).












